Triple therapy with artemether-lumefantrine plus amodiaquine versus artemether-lumefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an open-label, randomised, multicentre trial

Triple therapy with artemether-lumefantrine plus amodiaquine versus artemether-lumefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an open-label, randomised, multicentre trial

<strong>Background<br></strong> Late treatment failures after artemisinin-based combination therapies (ACTs) for falciparum malaria have increased in the Greater Mekong subregion in southeast Asia. Addition of amodiaquine to artemether–lumefantrine could provide an efficacious trea...

Повний опис

Бібліографічні деталі
Автори: Peto, TJ, Tripura, R, Callery, JJ, Lek, D, Nghia, HDT, Nguon, C, Thuong, NTH, van der Pluijm, RW, Dung, NTP, Sokha, M, Luong, VV, Long, LT, Sovann, Y, Duanguppama, J, Waithira, N, Hoglund, RM, Chotsiri, P, Chau, NH, Ruecker, A, Amaratunga, C, Dhorda, M, Miotto, O, Maude, RJ, Rekol, H, Chotivanich, K, Tarning, J, von Seidlein, L, Imwong, M, Mukaka, M, Day, NPJ, Hien, TT, White, NJ, Dondorp, AM
Формат: Journal article
Мова:English
Опубліковано: Elsevier 2022

Схожі ресурси